These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 31620616)

  • 21. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.
    Caussy C; Reeder SB; Sirlin CB; Loomba R
    Hepatology; 2018 Aug; 68(2):763-772. PubMed ID: 29356032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges.
    Ahmad MI; Khan MU; Kodali S; Shetty A; Bell SM; Victor D
    J Hepatocell Carcinoma; 2022; 9():477-496. PubMed ID: 35673598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.
    Van Wagner LB; Rinella ME
    Therap Adv Gastroenterol; 2011 Jul; 4(4):249-63. PubMed ID: 21765869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Lee C; Kim J; Jung Y
    Cells; 2019 Oct; 8(10):. PubMed ID: 31619023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment options for nonalcoholic fatty liver disease.
    Lam B; Younossi ZM
    Therap Adv Gastroenterol; 2010 Mar; 3(2):121-37. PubMed ID: 21180596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents.
    García-Compeán D; Kumar R; Cueto-Aguilera ÁND; Maldonado-Garza HJ; Villarreal-Pérez JZ
    Ann Hepatol; 2023; 28(4):100751. PubMed ID: 36002119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Younossi Z; Tacke F; Arrese M; Chander Sharma B; Mostafa I; Bugianesi E; Wai-Sun Wong V; Yilmaz Y; George J; Fan J; Vos MB
    Hepatology; 2019 Jun; 69(6):2672-2682. PubMed ID: 30179269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New drugs for NAFLD: lessons from basic models to the clinic.
    Reimer KC; Wree A; Roderburg C; Tacke F
    Hepatol Int; 2020 Jan; 14(1):8-23. PubMed ID: 31802390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
    Farrell GC; Larter CZ
    Hepatology; 2006 Feb; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis.
    Sayiner M; Lam B; Golabi P; Younossi ZM
    Therap Adv Gastroenterol; 2018; 11():1756284818811508. PubMed ID: 30479664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonalcoholic Fatty Liver Disease: Could It Be the Next Medical Tsunami?
    Bhandari P; Sapra A; Ajmeri MS; Albers CE; Sapra D
    Cureus; 2022 Apr; 14(4):e23806. PubMed ID: 35518541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
    Carr RM; Oranu A; Khungar V
    Gastroenterol Clin North Am; 2016 Dec; 45(4):639-652. PubMed ID: 27837778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
    Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
    Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
    Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
    Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Nonalcoholic fatty liver disease].
    Lemoine M; Serfaty L
    Presse Med; 2012 Feb; 41(2):169-89. PubMed ID: 21723084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Nonalcoholic steatohepatitis: pathogenesis and treatment].
    Park SH
    Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
    Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
    J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.